Investment Pitches

Pitch Summary:
Gilead has made phenomenal advancements in the healthcare space, particularly in the treatment of viral diseases such as HIV and hepatitis. Their innovations include groundbreaking antiviral therapies that have transformed these conditions from life-threatening diseases to manageable chronic illnesses. Gilead has also expanded into oncology and inflammation treatments, pushing the boundaries of therapeutic options for cancer and immune-related diseases.

BSD Analysis:
Gilead has successfully rebranded itself as an oncology and cell-therapy powerhouse in 2026, moving beyond its legacy role as a pure virology player. The stock recently hit all-time highs of $152.50 following the FDA's decision to remove label restrictions for Yescarta, making it the only CAR T-cell therapy available for certain lymphomas without prior use limitations. Financially, Gilead reported 2025 revenue of $29.4 billion with an industry-leading net margin of 39%. For 2026, investors are focused on the long-acting HIV injectable Sunlenca (lenacapavir) and its rollout for PrEP, which is expected to change adherence dynamics and capture significant market share.

Pitch Summary:
Simply put, Medtronic is developing some of the most innovative technology in healthcare today. Medtronic’s smart devices, including remote monitoring tools and implantable technologies, allow physicians to track patient health in real time, enabling quicker interventions and better outcomes. These advancements are particularly impactful in managing chronic conditions, such as heart disease, where continuous monitoring improves treatment efficacy.

BSD Analysis:
Medtronic has raised its fiscal 2026 outlook following a strong start to the year, with organic revenue growth now projected at 5.5% to 6.8%. The company’s Pulsed Field Ablation (PFA) franchise has emerged as a major catalyst, with cardiac ablation revenues skyrocketing nearly 50% (up 72% in the U.S.) due to high demand for the PulseSelect system. Non-GAAP EPS guidance for the full year has been narrowed to $5.60 to $5.66. While operating margins faced some compression due to tariff-related costs, management has successfully scaled manufacturing to support the acceleration of the Hugo robotic surgery platform and the Symplicity Spyral hypertension treatment.

Pitch Summary:
Aviation technology is big business, and GE Aerospace is a key player. But one of the attributes we like most about the company is that services account for about 70% of revenue, underscoring the importance of maintenance, repair, and overhaul (MRO) operations in its business model. The longevity of aircraft engines, which typically remain in service for over two decades, ensures a steady demand for the company’s services and parts.

BSD Analysis:
GE Aerospace enters 2026 with substantial momentum, issuing a full-year EPS guidance of $7.10 to $7.40, which sits above the market consensus of $7.12. In its recent late-January report, the company posted a Q4 beat with $11.9 billion in revenue (up 17.6% year-over-year), driven primarily by the high-margin commercial aftermarket segment. The firm's total backlog has reached an unprecedented $190 billion, providing multi-year visibility for services and parts. To reward shareholders, management recently raised the quarterly dividend by 30% to $0.47 per share. Analysts maintain a "Moderate Buy" rating with a price target of $314, viewing the company as the primary beneficiary of the global aviation "supercycle."

Pitch Summary:
The company serves as a middleman for collecting data; a heavy reliance on a single, third-party data collection tool; off-the-books employees in India; email marketing positions are being marketed as software job; Update 10/16/24 - Follow-up report. Update 10/25/24 - Follow-up report: Disclosed manipulated revenue guidance. Update 11/22/24 - Management lying on their recent media tour.

BSD Analysis:
Zeta Global offers AI-driven marketing automation and data analytics. Bears argue that customer churn, aggressive capitalization of costs, and crowded competition from Salesforce, Adobe, and HubSpot threaten growth. Revenue growth relies heavily on acquisitions, and organic momentum appears limited. With high leverage and limited free cash flow, skeptics expect dilution or refinancing pressure.

Pitch Summary:
SF REIT is positioned as a high-yielding bond proxy with a strong dividend yield of approximately 10%. The REIT benefits from stable cash flows, a high occupancy rate of 98%, and a strategic portfolio of logistics properties. The Hong Kong warehouse, which contributes significantly to net property income, is particularly valuable. Despite concerns about the broader Chinese real estate market, SF REIT's focus on logistics and its backing by SF Express provide a solid foundation for future growth.

BSD Analysis:
SF REIT's valuation appears attractive given its yield spread over the 10-year treasury rate, positioning it as a compelling income-generating asset. The REIT's portfolio is strategically located, with the Hong Kong warehouse being a key asset due to its proximity to major logistics hubs. While the mainland Chinese properties face potential rental reversions due to market oversupply, the REIT's financial structure, including its hedged gearing and potential benefits from future interest rate cuts, provides a buffer against these risks. The management's decision to decline overpriced acquisitions from SF Holdings and the potential for further asset acquisitions from its parent company suggest prudent governance. Additionally, SF Holdings' secondary listing plans indicate a focus on raising capital through equity markets rather than burdening SF REIT with overvalued asset purchases, which is a positive sign for minority shareholders.

Pitch Summary:
Net losses every single quarter after its IPO in 2004; overvalued (trading at x8.6 sales, 57% premium to its peers); insider cash-out; inflated key metrics (by up to 100%); the actual number of users are 30% less (bot accounts are accounted as Daily Active Users); extensive 'botting' problems; massive child safety & sexually abusive games; 'growth at all costs' approach;

BSD Analysis:
Roblox faces short pressure around slower monetization vs. user growth, reliance on unproven ad platform ramp, and rising infrastructure spend creating negative operating leverage. Concerns include developer payout tension and DAU skew to low-value geographies. Bears argue Street models assume too-optimistic ARPU inflection. Catalysts/risk checks: bookings per DAU, ad RPMs, cloud spend per user, and teen/adult adoption metrics. Counterpoints: platform network effects are powerful, but skeptics stress Roblox remains a long-duration story highly sensitive to capital costs and execution.

Pitch Summary:
Talkspace has undergone a significant transformation under new leadership, shifting from a cash-burning, low-growth company to a high-growth, cash-generative B2B provider. The company has diversified its revenue streams across Payor, Enterprise, and Consumer verticals, with the Enterprise segment being the most profitable. With a capital-light model and a substantial cash reserve, Talkspace has recently turned free cash flow positive and is on the brink of GAAP profitability. The onboarding of Medicare is expected to drive significant growth, increasing covered lives by 50%. The company's valuation is depressed, offering potential for substantial earnings upgrades and share price appreciation.

BSD Analysis:
Talkspace's strategic shift to focus on B2B services has positioned it for accelerated growth, particularly in the Payor segment, which is expected to benefit from the Medicare rollout. The company's commitment to maintaining fixed costs while expanding margins suggests potential for significant earnings surprises. The new CFO, with a background in investment, has initiated buybacks and insider stock purchases, signaling confidence in the company's future. Despite competitive pressures, Talkspace's large cash position provides downside protection and opportunities for strategic buybacks or M&A. The market's current undervaluation presents a compelling opportunity for multi-bagger returns if growth and margin expansion continue as projected.

Pitch Summary:
Fake financials (overstated profits which could be all fake); controlling shareholder has a history of underperformance; the company is being used as a piggy bank (loans to related parties); high delinquency rates; shady auditor;

BSD Analysis:
360 DigiTech is a Chinese fintech platform connecting borrowers with financial institutions. The short case highlights regulatory risk in China’s consumer lending sector, dependence on funding partners, and rising credit losses in subprime segments. Bears argue margins are flattered by aggressive provisioning assumptions and limited transparency in loan performance. Valuation is optically cheap but reflects geopolitical, accounting, and policy risks. Catalysts/risk checks: delinquency and charge-off trends, new PBoC regulations, and disclosure of funding partner economics. Counterpoints: secular demand for consumer credit is strong, but skeptics see QFIN as highly exposed to China’s policy unpredictability.

Pitch Summary:
Stock promotion; the company is a back-of-the-napkin nuclear idea; using interns to hype the company on news sites; the company shares the same space with an undisclosed party with hidden financial involvement; the CFO has positions in five other companies; unreasonable expenditures; poor service providers;

BSD Analysis:
NNE A/S provides engineering and consulting to pharma/biotech manufacturers. The short thesis emphasizes cyclicality in biotech capex, project-based revenue lumpiness, and high client concentration. Demand for facility design and validation services is tied to biotech funding, which has been pressured by capital market tightening. Margins are mid-teens but sensitive to utilization rates. Catalysts/risk checks: biotech funding cycles, backlog conversion, and contract win cadence. Counterpoints: NNE is a niche leader in pharma engineering, but skeptics argue valuation does not reflect the sector’s cyclical downside risks.

Pitch Summary:
General Electric was undervalued during the pandemic due to its exposure to the aviation sector, which faced significant challenges. Despite these difficulties, GE's strong market position in commercial jet engines and its scale advantages suggested a potential for recovery. The stock's depressed price offered a margin of safety, with the possibility of substantial returns even if air travel did not fully rebound.

BSD Analysis:
General Electric's aviation segment, which powers a significant portion of commercial jet engines, faced headwinds during the pandemic as air travel plummeted. However, the company's robust infrastructure and market share positioned it well for a recovery. The stock's valuation was attractive, trading at a significant discount to its historical norms. GE's management had outlined a clear strategy to navigate the downturn, focusing on cost reductions and operational efficiencies. The potential for a 15% perpetual return, even in a conservative scenario, highlighted the asymmetric risk-reward profile. Investors should consider the broader economic recovery and the aviation industry's rebound as key catalysts for GE's stock performance.

Pitch Summary:
25-years of fraud; the stock is worthless; misleading investors; company's technology is decade old; insiders cashing out; private placements at 90% lower than the market price; restated financials; numerous lawsuits;

BSD Analysis:
Laser Photonics develops industrial laser cleaning and cutting solutions. The short thesis stresses niche TAM, limited adoption vs. established cutting methods, and ongoing cash burn. Sales cycles are long, industrial customers conservative, and LASE lacks scale to compete with larger peers in fiber lasers. Execution has been uneven, with revenue lumpy and margins thin. Catalysts/risk checks: adoption rates in defense/industrial markets, backlog growth, and customer repeat orders. Counterpoints: the shift to laser-based eco-friendly cleaning could create tailwinds, but shorts see LASE as structurally too small and capital constrained.

Pitch Summary:
Using Halozyme's carrier enzymes, medication can now be injected directly under the skin, instead of being gradually added to the vein as an intravenous infusion over a period of several hours. It reduces the pressure on patients and lowers health care costs. Pharmaceutical companies such as Roche or Pfizer are responsible for the costs and risks associated with developing the medication, while Halozyme makes its money with treatments. A good and highly-profitable business model.

BSD Analysis:
Halozyme monetizes drug delivery technology that improves how therapies are administered, not what they treat. Its ENHANZE platform allows subcutaneous delivery of biologics, making life easier for patients and providers. Royalties drive a high-margin, asset-light revenue stream. Growth depends on partner pipelines, not internal blockbuster risk. Concentration risk exists if major partners stumble. Cash generation is strong relative to capital needs. This is not binary biotech exposure. It’s platform royalty economics tied to execution by others.

Pitch Summary:
Super Micro Computer (SMC) was one of the big winners of the AI wave of the last few months. Demand for data centre equipment was high, and SMC was able to deliver. After mind-boggling share price increases, we gradually sold our position. We are now selling the remaining position completely, as we do not like some related-party transactions.

BSD Analysis:
Super Micro is the arms dealer of AI server infrastructure — fast, flexible, and opportunistic. It doesn’t design the chips; it packages them into systems hyperscalers can deploy quickly. Growth has been explosive, but execution and supply chain management are constant stress tests. Margins are thinner than pure silicon plays, but velocity compensates. Customer concentration is high because AI demand is concentrated. Inventory discipline matters when cycles turn. This is not a moat-heavy franchise. It’s a speed-driven assembler riding an infrastructure surge.

Pitch Summary:
This Japanese producer of gearboxes and braking systems for trains was a secondary position in our sustainable equity fund; it was sold after quarterly numbers continued to show weakness. Despite the positive growth outlook in the robotics gearbox segment, profitability was still below our expectations.

BSD Analysis:
Nabtesco is a quiet monopoly in precision motion control, especially harmonic drives used in industrial robots. When automation scales, Nabtesco gets paid per joint. Barriers to entry are real because precision engineering at scale isn’t trivial. Demand swings with capex cycles, particularly in China. Margins reflect niche dominance rather than volume scale. Aerospace and transport systems add diversification beyond robotics. Execution risk is modest compared to peers chasing trendier automation themes. This is not flashy AI exposure. It’s mechanical infrastructure behind factory automation.

Pitch Summary:
In September, sales figures for Apple's new iPhone 16 were lower than expected; this also put pressure on suppliers’ share prices. Skyworks Solution makes the antennas that are built into Apple's devices; initially, the company’s share price fell following the release of the tepid sales numbers.

BSD Analysis:
Skyworks supplies RF components that sit inside connectivity infrastructure most consumers never notice. Smartphone cyclicality dominates headlines, but wireless complexity keeps increasing. Investors treat Skyworks as handset beta and miss diversification into IoT, automotive, and infrastructure. Content per device trends upward even in flat unit markets. Margins flex with volume, but design wins tend to stick. Capital allocation discipline matters more than revenue growth optics. This is connectivity infrastructure hidden inside consumer hardware cycles.

Pitch Summary:
It appears the US Congress thinks that the company's popular weight-loss injections are too expensive. The CEO was asked to appear before Congress. Another reason for the recent drop in Novo Nordisk’s share price: weak study results for the test compound Monlunabant. After 16 weeks, study participants in a Phase 2a study had a relatively small reduction in weight (7.1%).

BSD Analysis:
Novo is redefining metabolic medicine with therapies that shift healthcare economics at scale. Obesity and diabetes treatments are not incremental—they reset standards of care. Demand outstrips supply, moving risk from science to manufacturing execution. Investors debate peak sales prematurely while capacity and indications expand. Pricing power is grounded in measurable health outcomes. Pipeline depth extends beyond current blockbusters. This is pharmaceutical dominance backed by biology and scale.

Pitch Summary:
In the last annual report, the forecasts for the entire year continued to be positive; connections are expected to increase to over 2.9 million in the second half of the year. Moreover, financing and administration costs have also decreased and are expected to be lower in the second half of the year, so that additional free cash flows make way for a higher distribution.

BSD Analysis:
China Resources Gas is urban gas distribution infrastructure embedded in Chinese city life. Demand is tied to residential heating, cooking, and industrial usage that doesn’t swing wildly with headlines. Investors discount it for regulatory pricing caps and macro fears, yet volume growth and network expansion continue steadily. Integration of smaller municipal networks builds density and operational leverage. Margins are controlled by policy, but scale improves efficiency. Energy transition narratives often overlook the continued role of gas in urban China. This is utility-like cash flow trading under a geopolitical cloud.

Pitch Summary:
BioNTech is waking from its slumber. Share price developments suggest the possible presence of a buyer, although the higher share price may also be due to the latest BioNTech presentation at the European Cancer Conference (ESMO). The first diagram in the presentation shows BioNTech's approach of fighting cancer with a triad of immune modulation, mRNA injections and patient-specific Car-T therapies. Research progress is rapid, and the share price follows in its wake.

BSD Analysis:
BioNTech is priced like a post-pandemic cash burn story, but it’s sitting on one of the strongest balance sheets in biotech. COVID vaccine windfall profits weren’t the end of the story — they funded a broad oncology and mRNA pipeline without constant dilution. Investors fixate on declining vaccine revenue and miss how rare it is for a clinical-stage biotech to self-finance at scale. The oncology platform, particularly in individualized cancer vaccines and antibody combinations, carries asymmetric upside if execution lands. Partnerships with Pfizer and others reduce commercialization risk. Volatility is inevitable because milestones, not quarters, drive value here. This is platform biotech with cash and credibility, not a one-hit wonder. If even one late-stage oncology program works, the narrative flips fast.

Pitch Summary:
In terms of new investments, we highlight the acquisition of Midwich, a UK-based distributor of professional AV products that is also present in continental Europe, the United States and Asia. The AV distribution business has stable and predictable revenues because it maintains long-term relationships with both AV equipment suppliers, who need a partner with a good commercial presence, and customers, who need a distributor experienced in the latest technologies. Midwich has more than 24,000 steady customers and its suppliers have a growing dependence on it; it has a share of more than 40% of its top 20 suppliers. The stable nature of this business has enabled it to make more than 40 acquisitions, to strengthen its UK business, to position itself in the US and Europe and to add new technologies to its product portfolio. These acquisitions, together with the organic growth accumulated in recent years, have enabled Midwich to double its revenues and profits in the last 5 years and quadruple them in the last 10 years, while maintaining a leverage of 2x ebitda. We believe the company can maintain a similar pace of growth in the future because its sector is highly fragmented, and it can continue to gain market share. Although the company has achieved a new record high in revenues and gross margin in the first half of the year, the situation in the technology distribution sector in recent quarters has not been good and Midwich's sales have had a slight organic fall of 1%. Although profitability is still very good, the share price has fallen by more than 50%, creating a clear divergence between value and price which we have taken advantage of to buy. It is trading at 11% Free Cash Flow yield and less than 6x ebitda. Our target price is £5.5 per share, which offers a potential upside of 53%.

BSD Analysis:
Midwich’s moat is specialist distribution in professional AV where vendor relationships and technical support matter more than scale alone. Margins are higher than broadline distributors because expertise substitutes for price competition. That said, it’s still distribution—volume swings hit fast when corporate capex slows. M&A drives growth, raising integration and leverage discipline risk. Supplier concentration can tilt bargaining power away quickly. Pricing power is earned through service, not exclusivity. Operating leverage shows up in good years and vanishes in bad ones. The bull case is sustained demand for hybrid work and experiential tech. Midwich compounds if acquisition discipline stays tighter than the cycle.

Pitch Summary:
Craneware plc, a leading provider of healthcare financial management software in the US, benefits from network effects by offering solutions that become more valuable as more healthcare providers use them. It has developed its Trisus Cloud platform over recent years, from which it delivers its software services—helping nearly one in two US hospitals save money through the more efficient allocation of resources. Third party software providers are also being hosted on the Trisus platform. We anticipate network effects expanding further, as more companies are attracted towards this platform—further benefiting the end hospitals, as customers. As more hospitals and healthcare institutions adopt Craneware’s software, the data generated helps improve its algorithms and analytics, providing more accurate insights. This, in turn, attracts new clients who benefit from enhanced data-driven decision-making. The growing user base increases the efficiency of the platform, creating a positive feedback loop that strengthens Craneware's competitive position.

BSD Analysis:
Craneware sits at the intersection of healthcare IT and revenue cycle optimization, with sticky, mission-critical software that embeds deeply into hospital workflows. Its predominantly subscription and transaction-based revenues support high visibility and strong gross margins, while incremental margins on new business are attractive. The Trisus platform strategy should enhance cross-sell and up-sell opportunities, leveraging existing client relationships across nearly half of US hospitals. Valuation can look rich on traditional metrics during investment phases, but long-term growth plus operating leverage justify a quality premium. Key catalysts include deeper penetration of existing customers, expansion of partner solutions on Trisus, and continued regulatory complexity that increases demand for its analytics.